Financings In Brief
This article was originally published in The Gray Sheet
Executive Summary
Conceptus: Birth control device developer's plans for a secondary offering of 4 mil. shares of common stock are outlined in a recent filing with the Securities and Exchange Commission. The filing precedes a scheduled July 22-23 FDA Obstetrics & Gynecology Devices Panel meeting to review data on 400 patients treated with the Essure non-incisional, permanent birth control system, which has been granted fast-track status (1"The Gray Sheet" May 27, 2002, In Brief). The implant is expected to debut in the U.S. next year as an alternative to surgical tubal ligation and vasectomy, which currently account for about 1 mil. procedures annually. All of the shares will be offered by the company with UBS Warburg acting as the sole book-running manager. CIBC World Markets, Adams Harkness & Hill and SG Cowen are acting as co-managers...
You may also be interested in...
Essure birth control
FDA's Obstetrics and Gynecology Devices Advisory panel will review one-year data on 400 patients treated with Conceptus' non-incisional permanent birth control device at its July 22-23 meeting. Submitted April 19, the Essure PMA was granted expedited review, and the device could be approved and on the market by the end of 2002, Conceptus notes (1"The Gray Sheet" March 25, 2002, p. 21). In clinical trials, the device has shown 100% effectiveness in preventing pregnancy, leading to a projected one-year efficacy rate of 99.8%, the firm reports...
Cardiac Science Gains Public AED Platform With Survivalink's FirstSave
Cardiac Science Inc. will integrate its RHYTHMx ECD tachyarrhythmia detection and defibrillation software into Survivalink's FirstSave automatic external defibrillator (AED) product line following its acquisition of the Minneapolis-based firm, announced Feb. 14.
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.